NCT05050760

DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer

An Exploratory Study of the Efficacy and Safety of DCF Regimen Combined With Camrelizumab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma(ESCC)

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 55 (estimated)
• Sponsor: Xijing Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC

Detailed description

Primary outcome: To evaluate the safety and feasibility of DCF combined with camrelizumab in the treatment of locally advanced ESCC Secondary outcome: pathologic complete response (pCR)、Major Pathologic Response（MPR）、R0 resection rate、Objective response rate（ORR）、Disease free survival（DFS）、Relief rate and safety of dysphagia

Conditions

• ESCC

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.
DRUG	DCF	DCF:Oxaliplatin (85mg/ m\^2, IV D1,Q3W.Docetaxel: 60 mg/m\^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA\<1.25\^2,40 mg/time,1.25\^2\<BSA\<1.5\^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks

Timeline

• Start date: 2021-09-01
• Primary completion: 2023-12-01
• Completion: 2023-12-01
• First posted: 2021-09-21
• Last updated: 2023-01-31

Locations

1 site across 1 country: China